< 1 minute read
Jan. 17, 2022

Compound 24: a Brain-Penetrant, Type I LRRK2 Kinase Inhibitor

“compound 24”

LRRK2 kinase inhibitor preclinical, brain-penetrant from rational HTL and structure-guided opt. Journal of Medicinal Chemistry Merck & Co., Boston, MA

Drug Hunter Team

LRRK2 is a target of interest for Parkinson’s disease (e.g. DNL-151 ), but development had been slowed by concerns about potential lung toxicity of LRRK2 inhibitors. A Phase I study of a LRRK2 inhibitor in healthy volunteers had not shown human toxicity, though, and Biogen/Denali plan to proceed with Ph. III and Ph. IIb trials in 2022 . The [...]



Other molecules you may be interested in